Lonza to Launch the MODATM ES Next-Generation Electronic Batch Record Execution Platform at the Paperless Lab Academy 2019
Walkersville, MD (USA) / Basel (CH), 3 April 2019 – Lonza will launch the MODA™ ES Software Platform, a next-generation electronic batch record execution solution, at the Paperless Lab Academy 2019 from 9-10 April at Baveno, Lake Maggiore (IT). Building on Lonza’s extensive informatics know-how and contract manufacturing expertise, the new platform offers a flexible and user-friendly solution for consolidating and managing batch and quality data generated by non-automated manufacturing processes.
The MODA™ ES Software Platform has been designed to provide a cost-effective solution to batch record challenges.
Electronic batch records have been unattainable for most of the industry due to cost constraints and flexibility concerns. Lonza is changing that with the launch of the MODA™ ES Platform, which facilitates paperless execution across manufacturing and QC processes. The MODA™ ES Platform equals One Record, One Platform to move companies into the digital age and allow them to reap the benefits of efficiency, improved compliance, real-time reporting and expedited release of products to customers.
“The MODA™ ES Electronic Batch Record Execution Platform builds on Lonza’s unique manufacturing, quality- control and informatics expertise to bring a cost-effective, flexible and scalable solution to the market,” said Mike Goetter, Head of Global Sales – Bioscience Solutions. “This platform will enable manufacturing organizations to rapidly scale to a paperless workflow and empower them to make informed decisions while improving efficiency and compliance."
Introducing a different approach to informatics in life-science manufacturing
Attendees of the Paperless Lab Academy can learn more about the key features and benefits of Lonza’s new MODA™ ES Software Platform, including:
- Workflow-driven data entry applicable to batch records, sterility tests and cleaning forms
- A modular design allowing individual modules to be created, validated and used across different processes
- Standard methods for processing products of the same family, with the flexibility to vary the raw materials, fill volumes and equipment types used
- An electronic checklist enabling real-time review and approval
- Data integrity alert capability to trigger timely intervention and resolution of issues
- Seamless integration with other cGMP compliant electronic systems, as well as with analytical equipment, for effortless, reliable data transfer
For additional information or to request a demonstration, visit www.lonza.com/moda-es.
Lonza is an integrated solutions provider that creates value
along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Information
Manager Marketing Communications
Lonza Cologne GmbH
Tel +49 221 991990
Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.